Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Paroxetine 20mg tablets
0403030P0AAAAAA
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 123,091 |
|
Paroxetine 30mg tablets
0403030P0AAABAB
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 64,149 |
|
Paroxetine 10mg tablets
0403030P0AAAKAK
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 45,727 |
|
Paroxetine 40mg tablets
0403030P0AAALAL
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 15,303 |
|
Seroxat 20mg tablets
0403030P0BBAAAA
|
Seroxat | Paroxetine hydrochloride | Central Nervous System | 4,745 |
|
Seroxat 30mg tablets
0403030P0BBABAB
|
Seroxat | Paroxetine hydrochloride | Central Nervous System | 1,733 |
|
Seroxat 10mg tablets
0403030P0BBADAK
|
Seroxat | Paroxetine hydrochloride | Central Nervous System | 1,502 |
|
Paroxetine 10mg/5ml oral suspension sugar free
0403030P0AAAGAG
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 898 |
|
Seroxat 20mg/10ml liquid
0403030P0BBACAG
|
Seroxat | Paroxetine hydrochloride | Central Nervous System | 43 |
|
Paroxetine 10mg/5ml oral liquid
0403030P0AAAFAF
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | 8 |
|
Paroxetine 20mg/5ml oral liquid
0403030P0AAADAD
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | No data available |
|
Paroxetine 30mg/5ml oral liquid
0403030P0AAAEAE
|
Paroxetine hydrochloride | Paroxetine hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.